Impact of diagnosis and therapy on cognitive function in urea cycle disorders

Objective:Individuals with urea cycle disorders (UCDs) often presentwith intellectual and developmental disabilities. Themajor aim of this study was to evaluate the impact of diagnostic and therapeutic interventions on cognitive outcomes in UCDs.Methods:This prospective, observational, multicenter s...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Posset, Roland (VerfasserIn) , Baumgartner, Matthias R. (VerfasserIn) , Zielonka, Matthias (VerfasserIn) , Hoffmann, Georg F. (VerfasserIn) , Burgard, Peter (VerfasserIn) , Kölker, Stefan (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 2019
In: Annals of neurology
Year: 2019, Jahrgang: 86, Heft: 1, Pages: 116-128
ISSN:1531-8249
DOI:10.1002/ana.25492
Online-Zugang:Verlag, Volltext: https://doi.org/10.1002/ana.25492
Verlag: https://onlinelibrary.wiley.com/doi/10.1002/ana.25492
Volltext
Verfasserangaben:Roland Posset, Andrea L. Gropman, Sandesh C. S. Nagamani, Lindsay C. Burrage, Jirair K. Bedoyan, Derek Wong, Gerard T. Berry, Matthias R. Baumgartner, Marc Yudkoff, Matthias Zielonka, Georg F. Hoffmann, Peter Burgard, Andreas Schulze, Shawn E. McCandless, Angeles Garcia‐Cazorla, Jennifer Seminara, Sven F. Garbade, and Stefan Kölker for the Urea Cycle Disorders Consortium and the European Registry and Network for Intoxication Type Metabolic Diseases Consortia Study Group
Beschreibung
Zusammenfassung:Objective:Individuals with urea cycle disorders (UCDs) often presentwith intellectual and developmental disabilities. Themajor aim of this study was to evaluate the impact of diagnostic and therapeutic interventions on cognitive outcomes in UCDs.Methods:This prospective, observational, multicenter study includes data from 503 individuals with UCDs who hadcomprehensive neurocognitive testing with a cumulative follow-up of 702 patient-years.Results:Themeancognitivestandarddeviationscore(cSDS) was lower in symptomatic than in asymptomatic (p< 0.001,ttest)individuals with UCDs. Intellectual disability (intellectual quotient < 70, cSDS <−2.0) was associated with the respective subtype ofUCD and early disease onset, whereas height of the initial peak plasma ammonium concentration was inversely associated withneurocognitive outcomesin mitochondrial (proximal) rather than cytosolic (distal) UCDs. In ornithine transcarbamylase andargininosuccinate synthetase 1 deficiencies, we did notfind evidence that monoscavenger therapy with sodium or glycerolphenylbutyrate was superior to sodium benzoate in providing cognitive protection. Early liver transplantation appears to be bene-ficial for UCDs. It is noteworthy that individuals with argininosuccinate synthetase 1 and argininosuccinate lyase deficiencies identi-fied by newborn screening had better neurocognitive outcomes than those diagnosed after the manifestation offirst symptoms.Interpretation:Cognitive function is related to interventional and non-interventional variables. Early detection by new-born screening and early liver transplantation appear to offer greater cognitive protection, but none of the currentlyused nitrogen scavengers was superior with regard to long-term neurocognitive outcome. Further confirmation coulddetermine these variables as important clinical indicators of neuroprotection for individuals with UCDs.
Beschreibung:Gesehen am 24.10.2019
Beschreibung:Online Resource
ISSN:1531-8249
DOI:10.1002/ana.25492